| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A decade of clinical development of PARP inhibitors in perspective
|
Mateo, J.
|
|
|
30 |
9 |
p. 1437-1447
|
artikel
|
| 2 |
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
|
Türeci, O.
|
|
|
30 |
9 |
p. 1487-1495
|
artikel
|
| 3 |
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma
|
Mayer, E.L.
|
|
|
30 |
9 |
p. 1514-1520
|
artikel
|
| 4 |
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial
|
Holmes, E.M.
|
|
|
30 |
9 |
p. 1507-1513
|
artikel
|
| 5 |
Assumptions, damn assumptions and statistics
|
Simes, R.J.
|
|
|
30 |
9 |
p. 1415-1416
|
artikel
|
| 6 |
Cancer survivors: surveillance or not surveillance?
|
Santeufemia, D.A.
|
|
|
30 |
9 |
p. 1531
|
artikel
|
| 7 |
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
|
Lee, B.
|
|
|
30 |
9 |
p. 1472-1478
|
artikel
|
| 8 |
ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials
|
Montagut, C.
|
|
|
30 |
9 |
p. 1410-1413
|
artikel
|
| 9 |
Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications
|
Martens, S.
|
|
|
30 |
9 |
p. 1428-1436
|
artikel
|
| 10 |
Editorial board
|
|
|
|
30 |
9 |
p. ii-iii
|
artikel
|
| 11 |
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
|
Marchiò, C.
|
|
|
30 |
9 |
p. 1417-1427
|
artikel
|
| 12 |
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
|
Hofman, P.
|
|
|
30 |
9 |
p. 1448-1459
|
artikel
|
| 13 |
New designs in early clinical drug development
|
Mansinho, A.
|
|
|
30 |
9 |
p. 1460-1465
|
artikel
|
| 14 |
Optimizing panel-based tumor mutational burden (TMB) measurement
|
Budczies, J.
|
|
|
30 |
9 |
p. 1496-1506
|
artikel
|
| 15 |
Panel-based estimates of tumor mutational burden: characterizing unknown unknowns
|
Yang, W.
|
|
|
30 |
9 |
p. 1413-1415
|
artikel
|
| 16 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
|
Taieb, J.
|
|
|
30 |
9 |
p. 1466-1471
|
artikel
|
| 17 |
Reply to the letter to the editor ‘Cancer survivors: surveillance or not surveillance?’ by Santeufemia and Miolo
|
Holme, Ø
|
|
|
30 |
9 |
p. 1531-1532
|
artikel
|
| 18 |
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|
Wang, F.
|
|
|
30 |
9 |
p. 1479-1486
|
artikel
|
| 19 |
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer
|
Kudo, Y.
|
|
|
30 |
9 |
p. 1521-1530
|
artikel
|
| 20 |
Table of Contents
|
|
|
|
30 |
9 |
p. iv-v
|
artikel
|
| 21 |
Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations
|
Roda, D.
|
|
|
30 |
9 |
p. 1409-1410
|
artikel
|
Tijdschrift beschrijving